Today Jan 17, 2022
Event Image
Back to Events

CLL Abstracts from Atlanta

Wednesday Jan 12, 2022
Event Time 12:15 - 12:45 PM ET
Registration Closed
Event Faculty

Anthony Mato MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, NY
Event Faculty

Matthew S. Davids MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director, Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, MA

Learning Objectives
*Summarize the role of acalabrutinib in the management of chronic lymphocytic leukemia (CLL).
*Review recent clinical trial data regarding the use of acalabrutinib in the management of CLL.
*Describe novel and emerging clinical applications of acalabrutinib in managing CLL.

Program Description
Acalabrutinib is an investigational agent for management of CLL that may be safe and efficacious in the long-term control of this disease. It is being investigated both as monotherapy and in combination with other agents. A Phase 3 program is underway, abstracts of which have been presented at the 2021 American Society of Hematology (ASH) annual meeting. Here, we learn from leading experts what the latest findings are related to this agent, how to interpret these findings, and what to expect soon.

Event Sponsors

The content for this program has been independently developed by Clinical Care Solutions.